Indian Drug Majors Settle Generic Lawsuits
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Two of India's largest pharmaceutical companies - Ranbaxy Laboratories and Dr. Reddy's Laboratories - have settled litigation disputes with two major global drug firms
You may also be interested in...
Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait
MUMBAI - One more blockbuster drug will be available to U.S. citizens at a fraction of its brand price as India's Dr Reddy's announced the launch of generic versions of GlaxoSmithKline's anti-migraine drug Imitrex (sumatriptan)
Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait
MUMBAI - One more blockbuster drug will be available to U.S. citizens at a fraction of its brand price as India's Dr Reddy's announced the launch of generic versions of GlaxoSmithKline's anti-migraine drug Imitrex (sumatriptan)
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel - CEO Interview
MUMBAI - India's largest drug maker Ranbaxy is confident that the U.S. Department of Justice will soon withdraw its motion filed against the company, Ranbaxy CEO Malvinder Singh said in an interview with PharmAsia News